Lu-DOTA-TATE not checked
Novartis Pharmaceuticals · Lutetium Lu 177 dotatate
FollowEvery change as it happens, and a Monday email
Trials
10 active
12 in total · 12 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)”In the company’s words, NCT04711135 on ClinicalTrials.gov
- Tested for
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma, Extensive Stage Small Cell Lung Cancer, Glioblastoma
- Main trialPhase 2
- “This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.”In the company’s words, NCT04711135 on ClinicalTrials.gov
- Other names
- Lutathera · Lutetium Lu 177 dotatate · Lutetium oxodotreotide/dotatate
Other drugs for Gastroenteropancreatic Neuroendocrine Tumors
Coming up1
- 7 Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 17 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT06379217
- 17 NovCompletion date moved: 2026-10-09 to 2026-10-16 · ClinicalTrials.gov NCT06379217
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 12 Mar 2024 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | |
| Phase 1/2Active, not recruiting | 7 Mar 2028 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | |
| Phase 1Active, not recruiting | 3 Dec 2025 | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | |
| Phase 1Terminated | 16 Oct 2026 | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. | |
| Phase 2Authorised | not given | A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N | |
| Phase 2Authorised | not given | A PROSPECTIVE RANDOMIZED PHASE II STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® ([177LU]LU-DOTA-TATE) IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE TUMOR | |
| Phase 1/2Authorised | not given | Single-arm open-label phase I/II study in children and adolescents of 177Lu-DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptor (SSTR) (LuPARPed). | |
| Phase 2Authorised | not given | EORTC 2334-BTG: [177Lu]Lu-DOTATATE for recurrent MENingioma (LUMEN-1): a randomized phase II study | |
| Phase 2Authorised | not given | "Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases" "LUTARTERIAL" | |
| Phase 1Ended | not given | A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing somatostatin receptors | |
| Phase 1/2Authorised | not given | Randomized Interval Assessment trial of Lu177-Dotatate every 8 versus every 16 weeks in slowly progressive G1-2 advanced midgut neuroendocrine tumors (NETs) to Lower TOxicity. | |
| Phase 3Authorised | not given | Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia – a multi-center, prospective, open-label, two-arm parallel group, randomized, controlled, phase III study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026